Relation between the circular and linear form of the Elongator Acetyltransferase Complex Subunit 3 in the progression of triple-negative breast cancer.
Masoumeh BarznegarKarim RahimiParinaz MahdaviMohammad-Nazir MenbariNikoo DarvishiZakaria VahabzadehMohammad-Saied HakhamaneshiPedram AndalibiMohammad AbdiPublished in: Cell biochemistry and function (2022)
Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer (BC) that hardly responds to common treatment. Recent studies show that circ-ELP3 (Elongator Acetyltransferase Complex Subunit 3 or hsa-circ-0001785) is involved in the pathogenesis of several malignancies. The present study aimed to evaluate the possible role of this circRNA in the progression of TNBC cells and the possible relation between the circular and linear forms of the ELP3. We evaluated the circ-ELP3 and its host gene expression level in clinical samples and breast cancer cell lines. Using an expression vector, hsa-circ-0001785 was upregulated to investigate its role on cancer cell progression. After a transient transfection, we evaluated possible alterations in the cell cycle progression, cell viability, and cell proliferation. Quantitative real-time polymerase chain reaction analyses verified that circ-ELP3 and its host gene were significantly upregulated in TNBC tissues and breast cancer cells. Overexpression of circ-ELP3 markedly increases the cell viability and proliferation and also the formation of colonies in transfected cells compared to the controls. Briefly, our results showed that Circ-ELP3 and its host gene were significantly upregulated in TNBC. Circ-ELP3 is involved in TNBC progression and may exert its effects by indirectly regulating of ELP3 expression.
Keyphrases
- cell cycle
- cell proliferation
- gene expression
- induced apoptosis
- poor prognosis
- cell cycle arrest
- genome wide
- dna methylation
- signaling pathway
- breast cancer cells
- copy number
- transcription factor
- long non coding rna
- cell death
- protein kinase
- pi k akt
- brain injury
- mass spectrometry
- binding protein
- blood brain barrier
- combination therapy